ArticleFrontiers in oncology2026
Deep transfer learning for breast cancer detection in underserved regions.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: In Palestine, breast cancer is the leading cancer in women, constituting more than 34% of all cancer cases in women and 12% of all cancer related deaths. The Palestinian health care system is suffering from shortages, lack of advanced diagnostic equipment, among other issues. This study proposes a new two-step deep learning method for breast cancer detection in mammograms, with a particular focus on the potential of using it in low-resource settings like Palestine. The framework categorizes the tumor and adds a cost-effective and scalable diagnostic support tool that differentiates benign from malignant tumors. Methods: The proposed framework operates in two sequential stages. First, a U-Net architecture with a VGG16 encoder backbone, trained from scratch on the CBIS-DDSM mammography dataset, performs lesion segmentation. The CBIS-DDSM training set comprised 2,206 mammograms and the test set 576 images, all with ground truth binary masks. Second, a VGG16 classification model initialized with ImageNet pretrained weights classifies the segmented regions as benign or malignant. The classifier was tested on a subset of 34 patients from the Palestine Hospital dataset (12 benign, 22 malignant), which was used exclusively for external testing, in which no Palestine data were used in training or validation. Results: The U-Net segmentation model achieved a mean IoU of 0.70, Dice coefficient of 0.74, precision of 0.78, and recall of 0.71 on the CBIS-DDSM test set. The VGG16 classifier achieved 91% accuracy, 0.91 precision, 0.95 recall (malignant class), and AUC of 0.97 on the Palestine evaluation subset. Comparison against ResNet50 (85% accuracy) and MobileNet (82%) confirms the superiority of the proposed approach. Conclusion: The present study proposes a promising proof-of-concept deep learning pipeline for breast cancer detection. The results show that it is feasible in a low-resource environment, but would need to be validated on a larger annotated local dataset before deployment. The framework provides a guidance for scalable and cost-effective diagnostic assistance in underserved areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.